N@N

Sucampo Pharmaceuticals Management Reviews Awards Won During 2008

^{Published on 2008-12-24 05:35:22, Last Modified on 2008-12-24 05:37:08 - Market Wire}
 

BETHESDA, MD--([ BUSINESS WIRE ])--Senior management of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a leading international biopharmaceutical company, today noted the awards and honors that the company received during 2008. Sucampo was chosen as a finalist for two highly prestigious awards, the 2008 Prix Galien USA Award for The Best Pharmaceutical Product and the Scrip's "Pharma Company of the Year" Award. Sucampo's Chief Executive Officer was personally recognized for his contributions to the medical field of gastroenterology and the American Society of Consultant Pharmacists inducted Sucampo into its Hall of Fame. In addition, Sucampo ranked number four on the Deloitte Maryland Technology Fast 50; number 25 by the Washington Business Journal on their list of Fast Growing Companies in the Washington, D.C. area; and, number 100 on the 2008 Deloitte Technology Fast 500.

Ryuji Ueno, M.D., Ph.D., Ph.D., Founder, Chairman, and Chief Executive Officer, said, "As we review the past twelve months, we are thankful for having been recognized for our contributions to medical science and to the economic dynamism of the State of Maryland. All of us at Sucampo Pharmaceuticals are greatly honored to be recognized for a variety of characteristics. When we look forward to 2009, we hope that we will be able to equal, if not surpass, all of these accomplishments. The bar has been set at a high level, and we commit ourselves to achieving these goals."

Details on these honors include:

• In February, Dr. Ueno was awarded honorary membership in the American Gastroenterological Association (AGA) in recognition of his scientific accomplishments and their impact on gastroenterology. Chief among these accomplishments is the invention of AMITIZA^® (lubiprostone) the only FDA-approved drug for the treatment of Chronic Idiopathic Constipation (CIC) in adults and for Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. The AGA is an organization of more than 15,500 physicians, researchers and educators dedicated to advancing their science which involves the functions and disorders of the human digestive system.
• In August, AMITIZA^® was selected as a finalist for the 2008 Prix Galien USA Award for "The Best Pharmaceutical Product." Criteria for selection are: what was innovative in the course of the product's scientific development, application or clinical utility, was its discovery heuristic, and did society learn anything for the future of biomedical sciences from its introduction to the clinic. The Prix Galien, which originated in France, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines, was inaugurated in the United States in 2007.
• In September, Sucampo Pharmaceuticals was selected as one of five finalists for the Scrip's "Pharma Company of the Year" Award (small and medium-sized enterprises) for companies with revenues under $5 billion. This award recognizes outstanding achievement by a pharmaceutical company over the twelve-month period. Among the criteria that the judges evaluate are: growth of sales and profits, improving shareholder value, launch of significant new products and the creation of a new product pipeline. Finalists in 13 categories were selected by a panel of judges and Scrip WorldPharmaceutical News, a leading source of business news in the global pharmaceutical and biotechnology industries.
• Also in September, Sucampo was recognized by Deloitte & Touch LLP as the fourth highest growth member of the DeloitteMaryland Technology Fast 50. This annual award program selects winners based on the percentage revenue growth over five years from 2003 to 2007, are headquartered in Maryland and devotes a significant portion of revenues to the research and development of technology.
• In October, Sucampo was named by the Washington Business Journal as one of the Fastest Growing Companies in the Washington, D.C., area. Sucampo ranked number 25 among all companies in the Capital Area, and number 10 among the publicly-held companies on the list. Companies were selected on the basis of revenue growth over a three-year period, with 2005 revenue of more than $2 million and 2007 revenue of at least $10 million.
• In November, the American Society of Consultant Pharmacists (ASCP) inducted Sucampo into its Hall of Fame in recognition of its distinguished service to Consultant and Senior Care Pharmacy Practice. The Society's stated purpose is to achieve medical management and improved health outcomes for all older persons.
• Also in November, Sucampo ranked number 100 on the 2008 Deloitte Technology Fast 500. The national award is a ranking of the fastest growing life sciences, technology, media, and telecommunications companies in North America based on the percentage of fiscal year revenue growth over five years (2003-2007).

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development.

Sucampo Pharmaceuticals markets AMITIZA (lubiprostone) 24 mcg in the U.S. for Chronic Idiopathic Constipation in adults and AMITIZA 8 mcg in the U.S. to treat Irritable Bowel Syndrome with Constipation in adult women. Sucampo is also developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases and disorders affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, U.K., with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., headquartered in Tokyo with additional offices in Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit [ www.sucampo.com ].

AMITIZA^® is a registered trademark of Sucampo Pharmaceuticals, Inc.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors described in Sucampo Pharmaceuticals' filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2007 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.